Viatris (VTRS)
(Delayed Data from NSDQ)
$11.35 USD
-0.21 (-1.82%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $11.34 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.35 USD
-0.21 (-1.82%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $11.34 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth D Momentum B VGM
Zacks News
Theravance's (TBPH) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Thervance's (TBPH) fourth-quarter loss wider than expected. Revenues decline year over year.
Viatris' (VTRS) Q4 Earnings In-Line, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) reports in-line Q4 earnings but misses on sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris (VTRS) Matches Q4 Earnings Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 14.81% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q4 results are likely to be impacted by foreign exchange rate fluctuations. With the Biocon deal closed, investors await its impact on the 2023 guidance.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Viatris (VTRS) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort
by Zacks Equity Research
Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.
Zacks Earnings Trends Highlights: Disney, Take-Two, DuPont and Viatris
by Zacks Equity Research
Disney, Take-Two, DuPont and Viatris have been highlighted in this Earnings Trends article.
Making Sense of the Earnings Picture and Estimate Revisions
by Sheraz Mian
Looking at 2022 Q3 as a whole, total S&P 500 earnings are currently expected to be up +1.5% from the same period last year on +11.4% higher revenues. Excluding contributions from the Energy sector, Q3 earnings for the rest of the index would be -6.0%
Making Sense of the Earnings Picture and Estimate Revisions
by Sheraz Mian
Looking at 2022 Q3 as a whole, total S&P 500 earnings are currently expected to be up +1.5% from the same period last year on +11.4% higher revenues. Excluding contributions from the Energy sector, Q3 earnings for the rest of the index would be -6.0%
Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.
Viatris (VTRS) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.
Viatris (VTRS) Q3 Earnings Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 4.88% and 1.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -6.25% and 1.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed at $10.25 in the latest trading session, marking a +1.18% move from the prior day.
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris (VTRS) Q3 results are likely to be impacted by foreign exchange rate fluctuations. An update on the deal with Biocon is also expected along with the results.
Viatris (VTRS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed at $9.97 in the latest trading session, marking a +1.94% move from the prior day.
Viatris (VTRS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $9.61, marking a +0.63% move from the previous day.
Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris
by Zacks Equity Research
Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in the United States
Why Is Viatris (VTRS) Down 10% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for Aug 9, 2022
by Zacks Equity Research
Companies in The News Are: GOLD,HE,BNTX,VTRS
Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.